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BACKGROUND: We assessed the activity of gemcitabine (G) and cisplatin/gemcitabine (C/G) in patients with locally advanced (LA) or
metastatic (M) (advanced) biliary cancers (ABC) for whom there is no standard chemotherapy.
METHODS: Patients, aged X18 years, with pathologically confirmed ABC, Karnofsky performance (KP) X60, and adequate
haematological, hepatic and renal function were randomised to G 1000mgm
 2 on D1, 8, 15 q28d (Arm A) or C 25mgm
 2
followed by G 1000mgm
 2 D1, 8 q21d (Arm B) for up to 6 months or disease progression.
RESULTS: In total, 86 patients (A/B, n¼44/42) were randomised between February 2002 and May 2004. Median age (64/62.5 years),
KP, primary tumour site, earlier surgery, indwelling biliary stent and disease stage (LA: 25/38%) are comparable between treatment
arms. Grade 3–4 toxicity included (A/B, % patients) anaemia (4.5/2.4), leukopenia (6.8/4.8), neutropenia (13.6/14.3),
thrombocytopenia (9.1/11.9), lethargy (9.1/28.6), nausea/vomiting (0/7.1) and anorexia (2.3/4.8). Responses (WHO criteria, % of
evaluable patients: A n¼31 vs B n¼36): no CRs; PR 22.6 vs 27.8%; SD 35.5 vs 47.1% for a tumour control rate (CRþPRþSD) of
58.0 vs 75.0%. The median TTP and 6-month progression-free survival (PFS) (the primary end point) were greater in the C/G arm
(4.0 vs 8.0 months and 45.5 vs 57.1% in arms A and B, respectively).
CONCLUSION: Both regimens seem active in ABC. C/G is associated with an improved tumour control rate, TTP and 6-month PFS.
The study has been extended (ABC-02 study) and powered to determine the effect on overall survival and the quality of life.
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Biliary tract tumours are rare tumours accounting for 0.7% of
malignant tumours in adults, with approximately 1200 new cases
registered each year in England and Wales. The UK mortality rate is
approximately 23 per million population with 1- and 5-year survival
figures for adults diagnosed in England and Wales during 1986–1990
of 22 and 9%, respectively (Coleman et al, 1996).
Surgical resection, determined by the location, extent of disease
and involvement of surrounding tissues, offer the only chance of
long-term cure. Unfortunately, the resectability rates are generally
low; survival after surgical resection varies widely between centres
(range 23–50% at 5 years) (Klempnauer et al, 1997). Although this
is better than the 5-year survival seen in pancreatic cancer (10%
with surgery alone, increased to approximately 20% with adjuvant
chemotherapy) (Neoptolemos et al, 2004; Oettle et al, 2007), the
majority of patients with resected biliary tract cancers still develop
recurrent or metastatic disease. In the presence of unresectable
disease, patients with biliary tumours often present with the
additional clinical problem of biliary obstruction. Patients need
to be adequately palliated before further treatment (e.g. chemo-
therapy) either by endoscopic or percutaneous biliary stenting.
Most patients present with tumours that are too advanced
for surgical resection, and the function of radiotherapy or Received 16 April 2009; revised 24 June 2009; accepted 3 July 2009
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schemotherapy at present remains uncertain. Before initiating this
study, a review of the chemotherapy regimens used for the
treatment of biliary tract cancers showed that the majority of
chemotherapy regimens used to date have been 5-FU based (Smith
et al, 1984; Kajanti and Pyrhonen, 1994; Comella et al, 1996;
Gebbia et al, 1996; Patt et al, 1996, 1999; Ducreux et al, 1998;
Raderer et al, 1999; Choi et al, 2000). As a single agent, intravenous
5-FU has a response rate of 25–32% (Raderer et al, 1999; Choi
et al, 2000). The addition of cisplatin (Ducreux et al, 1998; Patt
et al, 1999), doxorubicin (Patt et al, 1999), epirubicin (Kajanti and
Pyrhonen, 1994), hydroxyurea (Gebbia et al, 1996) or methotrexate
(Kajanti and Pyrhonen, 1994; Comella et al, 1996) seems to add
little in terms of response rate in these phase II studies. The oral
fluoropyrimidine pro-drug, capecitabine, has shown promising
results (Lozano et al, 2000) in 26 patients with cholangiocarcino-
mas and gallbladder cancers, but confirmation of efficacy in a
randomised phase III study is not available.
Docetaxel has been found to be active and well tolerated on the
basis of a 25% RR and 31% stabilisation of disease in a mixed
group of gallbladder (n¼13), cholangiocarcinomas (n¼4) and
ampullary tumours (n¼3) (Agelaki et al, 1999).
The adoption of gemcitabine as the standard of care for patients
with pancreatic cancer (Casper et al, 1994; Rothenberg et al, 1996;
Burris et al, 1997; Storniolo et al, 1997) led to interest in the use of
gemcitabine for other hepatobiliary tumours. In the usual dosing
regimen, responses of 16–42% have been obtained (Raderer et al,
1999; Gallardo et al, 2000). Some investigators have looked at
altering the schedule to improve efficacy; Dragovich et al (2000)
found that the fixed dose rate (at 10mgm
 2min
 1) did not
enhance efficacy and that the response rates with intra-arterial
administration are not significantly higher than intravenous
historical controls (Weissmann and Ludwig, 1999). Initial data
from a continuous-infusion regimen showed this to be well
tolerated and activity data were awaited (Eckel et al, 2000). The
median survivals reported in these early phase II studies ranged
from 5.7 to 11þ months.
Cisplatin is widely used in combination chemotherapy and there
are synergistic effects when it is combined with gemcitabine.
On account of this, the combination of cisplatin and gemcitabine is
widely used in other cancers (including lung, head and neck,
pancreatic and bladder cancers). The specific sequence of cisplatin
followed by gemcitabine seems to be optimal in pre-clinical testing
(Braakhuis et al, 1995; Theodossiou et al, 1998). To exploit this
additive/synergistic effect, we used a regimen that delivered both
agents at every dosing time point. Our group has previously shown
this regimen to be well tolerated and easily deliverable as a 2-h out-
patient infusion regimen in patients with pancreatic cancer.
Although the dose of cisplatin seems low (25mgm
 2), it equates
to a dose of 50mgm
 2 per 21-day cycle, and earlier attempts at
increasing the dose intensity resulted in more dose delays and
interruptions (Clayton et al, 2006).
The aim of this study was to evaluate both single-agent
gemcitabine and the cisplatin/gemcitabine doublet in patients
with locally advanced or metastatic biliary tract tumours
(cholangiocarcinomas and gallbladder carcinomas) using a rando-
mised phase II design. A follow-on phase III trial was also planned
depending on the relative merits of each treatment arm in terms of
activity, feasibility and tolerability.
The primary objective was to assess the efficacy in terms of
6-month progression-free survival (PFS) for both treatment arms.
Secondary objectives included response rate, overall survival and
toxicity assessment.
MATERIALS AND METHODS
Study design
This is a multicentre randomised phase II study of weekly (for 3
weeks in every four-week cycle,  6 cycles) doses of gemcitabine
1000mgm
 2 as a single agent or preceded by cisplatin 25mgm
 2
(on a 2 weeks in every three-week cycle,  8 cycles) in patients
with histologically or cytologically verified, non-resectable or
recurrent/metastatic cholangiocarcinoma (intra- or extrahepatic),
gallbladder or ampullary carcinoma (Figure 1).
Eligibility criteria included the following: no earlier chemo-
therapy or radiotherapy, Karnofsky performance (KP) status X60,
Eligible patient: locally advanced or metastatic 
cholangiocarcinoma or biliary carcinomas, no previous 
chemotherapy (n=80) 
Randomise
Stratified (locally advanced vs. metastatic)
Gemcitabine 1000 mg m–2
D1, 8, 15 q28d
up to 24 weeks
Arm B 
(n=40)
Cisplatin 25 mg m–2 + 
Gemcitabine 1000 mg m–2
D1, 8 q21d 
up to 24 weeks 
Upon disease progression, further management left to the treating 
clinician’s discretion
Arm A 
(n=40)
Figure 1 Trial schema.
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sage X18 years, predicted survival X12 weeks, adequate bone
marrow, liver, renal and cardiac function, adequate biliary
drainage, no known brain metastases, no previous malignancy,
no serious concurrent medical illness and, where applicable,
approved methods of birth control. All patients gave written
informed consent and the trial was conducted in accordance with
ICH-GCP standards and the Declaration of Helsinki. Each
participating institution was required to have approval by their
respective local research ethics committee.
Treatment
Patients were randomised to receive gemcitabine 1000mgm
 2
intravenous infusions on days 1, 8 and 15 of each 28-day cycle or
cisplatin 25mgm
 2 followed by gemcitabine 1000mgm
 2 by
intravenous infusions on days 1 and 8 of each 21-day cycle.
A minimum of two cycles was required to assess tumour status
and the maximum period of therapy was 24 weeks (six cycles
of single-agent gemcitabine and eight cycles of cisplatin/
gemcitabine).
Patients were assessed after every cycle for adverse events;
toxicities were graded according to the Revised Common Toxicity
grading Criteria version 2.0. A complete blood count, biochemistry,
physical examination and urine analysis were also assessed at the
commencement of each cycle. Radiological assessment by CT scan
every 12 weeks during treatment determined the tumour status.
Objective tumour response was evaluated according to the WHO
criteria by local investigators; central radiology review was not
performed.
Treatment was given until progressive disease (or until
completion of the planned 24 weeks of therapy), unacceptable
toxicity or patient refusal. Thereafter, patients continued to be
followed up for survival data. Patients who had not progressed by
the end of the treatment period continued to have CT scans at
3-month intervals until such time as there was evidence of disease
progression.
Statistical design
These are both relatively new regimens for this type of tumour.
This randomised phase II study aimed at assessing the relative
merits of both regimens before proceeding to a full phase III study.
The trial consisted of 80 patients, randomised 1:1 between
the two regimens. Patients were stratified, at randomisation, for
the extent of disease (locally advanced vs metastatic). Given the
difficulties in measuring the response rate in this group of patients
(where often the disease is concentric around a bile duct), the
primary end point was PFS at 6 months from the time of
randomisation. Assuming a baseline 40% PFS at 6 months for the
gemcitabine arm, the cisplatin/gemcitabine combination arm
would be considered ‘favourable’ if there was a 10% improvement
in this end point (to 50%) with an acceptable toxicity profile.
A total of 40 patients in each arm would estimate this 6-month
progression-free rate with an accuracy of ±15.5%.
This study was not powered to permit formal statistical
comparison between the two treatment arms. However, it would
allow an initial assessment of the regimens in terms of a 6-month
progression-free rate, response rate, overall survival and toxicity
with a view to a follow-on phase III study.
RESULTS
From February 2002 to May 2004, 86 patients (median age 63
years, range 29–84 years with a slight preponderance of women)
were randomised from 15 institutions, 44 to the gemcitabine arm
and 42 to the cisplatin/gemcitabine combination (Figure 2).
Baseline characteristics including median age, sex, performance
score (KP), primary tumour site (cholangiocarcinoma, gallbladder
95 patients assessed
9 patients excluded
(2 declined)
(7 failed screening)
44 patients allocated to gemcitabine 
alone 
44 patients received allocated 
intervention
86 patients randomised
42 patients allocated to cisplatin +
gemcitabine
42 patients received allocated
intervention
0 patients ongoing treatment
44 patients discontinued
intervention
(14 completion of treatment)
(11 disease progression)
(2 adverse events)
(3 sepsis/biliary obstruction)
(9 death)
(5 other)
0 patients ongoing treatment
42 patients discontinued intervention
(19 completion of treatment)
(9 disease progression)
(3 adverse events)
(1 sepsis/biliary obstruction)
(7 death)
(3 other)
44 patients included in primary
efficacy analysis (progression-free
survival, ITT)
44 patients analysed for adverse
events
31 patients analysed for response rate
42 patients included in primary
efficacy analysis (progression-free
survival, ITT)
42 patients analysed for adverse
events
36 patients analysed for response rate
Figure 2 Trial profile.
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sor ampullary cancer), earlier surgery, indwelling biliary stent and
disease stage (locally advanced vs metastatic) are comparable
between the treatment arms (Table 1).
Toxicity
Both treatments were well tolerated and the toxicities were much
as expected from the experience in other tumours (Table 2). In
keeping with the nature of biliary tract cancers, non-neutropenic
infections were fairly common at some point during the treatment
(mostly cholangitis with biliary obstruction), occurring with
similar frequency in both arms and usually requiring admission
to hospital for biliary drainage and antibiotic therapy. The most
frequently reported (410% incidence) grade 3–4 drug-related
adverse events on the single gemcitabine arm were transaminitis
(13.6%) and neutropenia (also 13.6%), whereas in the combination
arm, lethargy, neutropenia, thrombocytopenia and transaminitis
occurred in 28.6, 14.3, 11.9 and 11.9% of cases, respectively.
Although the incidence of lethargy was higher in the combination
arm (28.6 vs 9.1% in the gemcitabine-alone arm), this did not
result in an increase in withdrawal from treatment (n¼3i n
combination arm vs n¼2 in gemcitabine-alone arm), Figure 2.
Response
A total of 67 patients were evaluable for tumour response in
accordance with the protocol and WHO tumour response criteria,
31 on the gemcitabine arm and 36 on the cisplatin/gemcitabine
arm. No complete tumour responses were observed. In total, 7
patients on the gemcitabine arm had a partial response compared
with 10 patients on the cisplatin/gemcitabine arm (PR 22.6 vs
27.8%). In addition, 11 patients had stable disease on gemcitabine
alone vs 17 on the combination (SD 35.5 vs 47.2%) The tumour
control rate (CRþPRþSD) was 58.0 vs 75.0% in favour of the
cisplatin/gemcitabine combination. In total, 13 and 9 patients,
respectively, had progressive disease (Table 3).
Patients were required to discontinue therapy on radiological
evidence of disease progression or unacceptable toxicity. Table 4
shows that the mean duration of time on treatment was longer for
Table 1 Patient and tumour characteristics
GEM CIS/GEM Total
No. of patients 44 42 86
Male 19 (43.2%) 17 (40.5%) 36 (41.9%)
Female 25 (56.8%) 25 (59.5%) 50 (58.1%)
Median age, years (range) 64 (29–84) 63 (38–76) 63 (29–84)
Primary tumour site
Intrahepatic CC 7 (15.9%) 12 (28.6%) 19 (22.1%)
Extrahepatic CC 11 (25.0%) 9 (21.4%) 20 (23.3%)
Cholangiocarcinoma NOS 10 (22.7%) 10 (23.8%) 20 (23.3%)
Gallbladder 12 (27.3%) 10 (23.8%) 22 (25.6%)
Ampullary cancer 4 (9.1%) 1 (2.4%) 5 (5.8%)
Stage
Locally advanced 11 (25.0%) 16 (38.1%) 27 (31.4%)
Metastatic 33 (75.0%) 26 (61.9%) 59 (68.6%)
Earlier therapy
Curative surgery 10 (22.7%) 3 (7.1%) 13 (15.1%)
Palliative surgery 10 (22.7%) 13 (31.0%) 23 (26.7%)
Laparotomy only 17 (38.6%) 12 (28.6%) 29 (33.7%)
Biliary stent insertion 23 (52.3%) 25 (59.5%) 48 (55.8%)
Radiotherapy 3 (6.8%) 0 (0.0%) 3 (3.5%)
Karnofsky performance score
100 4 (9.1%) 5 (11.9%) 9 (10.5%)
90 17 (38.6%) 18 (42.9%) 35 (40.7%)
80 19 (43.2%) 12 (28.6%) 31 (36.0%)
70 2 (4.5%) 6 (14.3%) 8 (9.3%)
60 1 (2.3%) 1 (2.4%) 2 (2.3%)
NR 1 (2.3%) 0 (0.0%) 1 (1.2%)
CC¼cholangiocarcinoma; CIS/GEM¼cisplatin/gemcitabine; NOS¼not otherwise
specified; NR¼not recorded.
Table 2 Grade 3–4 toxicity by treatment arm (given as incidence of
toxicity by patient)
GEM CIS/GEM
Toxicity
No. of patients
n¼44
No. of patients
n¼42
Haematological adverse events
Anaemia 2 (4.5%) 1 (2.4%)
Leucopenia 3 (6.8%) 2 (4.8%)
Neutropenia 6 (13.6%) 6 (14.3%)
Thrombocytopenia 4 (9.1%) 5 (11.9%)
Non-haematological adverse events
Lethargy 4 (9.1%) 12 (28.6%)
Infection (non-neutropenic) 7 (15.9%) 8 (19.0%)
Bilirubin 9 (20.5%) 5 (11.9%)
Transaminases 6 (13.6%) 5 (11.9%)
Vomiting 0 (0.0%) 3 (7.1%)
Oedema 2 (4.5%) 2 (4.8%)
Anorexia 1 (2.3%) 2 (4.8%)
Pain 1 (2.3%) 2 (4.8%)
Diarrhoea 0 (0.0%) 2 (4.8%)
Dyspnoea 0 (0.0%) 2 (4.8%)
Constipation 1 (2.3%) 1 (2.4%)
Infection (neutropenic) 0 (0.0%) 1 (2.4%)
Stomatitis 0 (0.0%) 1 (2.4%)
Renal 0 (0.0%) 1 (2.4%)
Neuropathy 1 (2.3%) 0 (0.0%)
Nausea 0 (0.0%) 0 (0.0%)
Alopecia 0 (0.0%) 0 (0.0%)
CIS/GEM¼cisplatin/gemcitabine.
Table 3 Radiological response to treatment (WHO criteria, for
evaluable patients only)
GEM N¼31* CIS/GEM N¼36*
Not evaluable* 13/44 (29.5%) 6/42 (14.3%)
Complete response (CR) 0 0
Partial response (PR) 7 (22.6%) 10 (27.8%)
Stable disease (SD) 11 (35.5%) 17 (47.2%)
Progressive disease (PD) 13 (41.9%) 9 (25.0%)
Response rate (CR+PR) 7 (22.6%) 10 (27.8%)
Tumour control rate (CR+PR+SD) 18 (58.0%) 27 (75.0%)
Not assessable 13 (25.0%) 6 (11.9%)
CIS/GEM¼cisplatin/gemcitabine.
*Patients were not required to have measurable disease at study entry.
Table 4 Delivery of therapy by treatment arm
Gemcitabine
n¼44
Cisplatin/gemcitabine
n¼42
No of cycles given 158 246
Duration of cycle 4 weeks 3 weeks
Mean duration of treatment
(weeks)
15.7 18.7
Median number of cycles 3 7.5
Range 1–6 1–8
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spatients receiving cisplatin/gemcitabine vs gemcitabine alone
(18.7 vs 15.7 weeks, respectively).
Survival
The primary end point for this study was 6-month PFS. At the time
of analysis, all patients had progressed. The 6-month PFS for the
gemcitabine-alone arm was 45.5% (95% CI 30.5–59.3%) vs 57.1%
(95% CI 41.0–70.3%) for the combination arm with median PFSs
of 4.0 and 8.0 months, respectively, in each of the arms (Figure 3).
Overall survival data have been censored by the Data Safety
Monitoring Committee, as the study is not powered to allow a
comparison between the arms in terms of survival and all patients
in this study will be included in the survival statistics in the follow-
on phase III study (statistically powered for survival).
DISCUSSION
Surgical resection remains the treatment of choice for patients with
biliary tract cancers and, to date, there are no conclusive data to
support the routine use of chemotherapy in patients diagnosed
with locally advanced, inoperable, recurrent or metastatic disease.
A number of limitations have contributed to this lack of
evidence base including the relative infrequency of these cancers,
particularly in Western countries, with any individual institution
having small numbers of patients. A recent review of all published
(and abstract) biliary tract cancer trials revealed that the numbers
of patients per trial ranged from 5 to 65 (with a mean of 25.1
patients) (Eckel and Schmid, 2007). Our ABC-01 study, with 86
patients is, therefore, the largest study reported in the literature to
date, enabled by a national, UK-wide National Cancer Research
Network (NCRN) collaboration.
Another limitation is that biliary tract tumours are notoriously
difficult to evaluate for response or progression. Although some
patients have parenchymal lesions that lend themselves to
objective measurement, many patients have malignant sclerosing
disease along bile ducts, which, even in the presence of a response,
may show little change on conventional imaging. In total, 19 of our
86 patients (22%) did not have evaluable disease. In their pooled
analysis, Eckel and Schmid have shown that the response rate
correlates poorly with overall survival (correlation coefficient
r¼0.2, P¼0.043). Tumour control rate fares a little better
(r¼0.26, P¼0.024), although time to tumour progression seems
the best surrogate marker of activity in this disease group with the
best correlation with overall survival (r¼0.73, Po0.0005) (Eckel
and Schmid, 2007). This finding validates the primary end point
chosen for our study, which was based on radiological or clinical
progression of disease. Our observation of improved 6-month PFS
from 45.5% (gemcitabine alone) to 57.1% (cisplatin/gemcitabine
combination) was close to our approximated statistical assumption
of 10% benefit on which our cohort size was based. Moreover,
patients who received gemcitabine alone fared a little better than
we had assumed (initial assumption of 6-month PFS: 40%). Given
the limitations of conventional cross-sectional imaging, the use of
functional imaging (with, for example, FDG-PET or FLT-PET) may
provide more reliable surrogates of activity to hasten drug
development for the treatment of biliary tract cancers (as is
currently being investigated for other tumour types, e.g. colorectal
cancer (Francis et al, 2004)).
Thus, both treatment arms in ABC-01 showed activity. However,
combination chemotherapy resulted in a marginally better
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Figure 3 Kaplan–Meier curve of progression-free survival by treatment arm as a function of time.
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sresponse rate (CRþPR: 27.8 vs 22.6%), and superior tumour
control rate (CRþPRþSD: 75.0 vs 58.0%), broadly in line with
that seen in previous studies (Dingle et al, 2005). Both treatment
arms were well tolerated, although patients who received doublet
therapy showed a significant increase in lethargy (28.6 vs 9.1%);
the effect of this finding on the quality of life was not explored in
this study. Neither did we mandate serum CA 19-9 measurement,
as this was not widely available as a standard test at the outset of
the study.
The aforementioned review found that most of the studies in the
literature were small phase II studies evaluating mostly fluoro-
pyrimidine- and gemcitabine-based therapies (others include
taxanes, anthracyclines, mitomycin-C and irinotecan) (Eckel and
Schmid, 2007) and two other randomised phase II studies have
been reported in the literature: an EORTC study comparing
high-dose 5-FU with or without cisplatin (Ducreux et al, 2005)
and another study comparing mitomycin-c with gemcitabine vs
mitomycin-C and capecitabine (Kornek et al, 2004).
There is a paucity of randomised phase III data available. In one
phase III study, 90 patients with both pancreatic (n¼53) and
biliary tumours (n¼37) were randomised to receive either best
supportive care (BSC) or BSC with 5-FU, etoposide and leucovorin
(FELV) chemotherapy (etoposide was omitted for elderly patients
because of the high incidence of mucositis). There was a
statistically significant survival advantage from the chemotherapy
arm in terms of survival (6 vs 2.5 months, Po0.01, despite a
crossover to treatment of eight patients allocated to the BSC arm),
although the study was underpowered to make any conclusion
regarding biliary tract cancers (Glimelius et al, 1996). A more
recent study by Rao et al (2005) built on the findings of this study
by randomising 54 patients to either FELV chemotherapy or to the
epirubicin, cisplatin and continuous-infusion 5-FU (ECF) regimen.
The authors found the ECF regimen to be less toxic than FELV
with a similar response rate, symptom resolution and failure-free
survival, although it did not improve survival. The study, which
had planned to recruit 166 patients, closed because of slow accrual,
showing the difficulty of large studies in this patient group.
ABC-01, although not powered to permit a formal comparison
between the two treatment arms, has provided useful information
in terms of 6-month progression-free rate, response rate, overall
survival and toxicity. It has been followed by ABC-02, a
randomised phase III study, also run under the auspices of the
UK-NCRN, comparing the same two treatment arms but powered
to detect a survival advantage as the primary end point. In
addition, the effect of either treatment on the quality of life and
changes in serum CA19-9 will be reported.
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